Loading
The 2025 trial in which a wearable device delivering alternating electric fields to the abdomen, added to chemotherapy, lengthened survival in locally advanced pancreatic cancer from about 14 to 16 months and delayed the onset of pain.
PANOVA-3 randomised 571 patients with newly diagnosed unresectable locally advanced pancreatic adenocarcinoma to gemcitabine 1,000 mg/m2 and nab-paclitaxel 125 mg/m2 on days 1, 8 and 15 of 28-day cycles with or without tumour treating fields. Overall survival, the primary endpoint, was 16.2 months (95 percent confidence interval 15.0 to 18.0) with the device against 14.2 months (12.8 to 15.4) without (hazard ratio 0.82, 0.68 to 0.99, P = 0.039). Progression-free survival, local progression-free survival and response rate were not improved. Pain-free survival was 15.2 versus 9.1 months (hazard ratio 0.74, P = 0.027) and distant progression-free survival, analysed post hoc, 13.9 versus 11.5 months (hazard ratio 0.74). Device-related skin adverse events occurred in 76.3 percent of patients, mostly mild to moderate, grade 3 in 7.7 percent, with no additive systemic toxicity.
The evidence behind the 2026 approval of Optune Pax for locally advanced disease, the first new approval in that setting in decades, and an unusual case of a survival gain without a progression-free survival gain.
Shares Eric Van Cutsem, Gemcitabine + nab-paclitaxel, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Journal of Clinical Oncology and the tag pancreatic-evidence.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Journal of Clinical Oncology, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Overall survival (OS), Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Journal of Clinical Oncology, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Journal of Clinical Oncology, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Overall survival (OS), Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.